Wellington Management Group LLP Has $127.13 Million Position in Xenon Pharmaceuticals Inc. $XENE

Wellington Management Group LLP boosted its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 0.3% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,789,197 shares of the biopharmaceutical company’s stock after purchasing an additional 11,586 shares during the period. Wellington Management Group LLP owned about 4.95% of Xenon Pharmaceuticals worth $127,128,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its holdings in shares of Xenon Pharmaceuticals by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 69,529 shares of the biopharmaceutical company’s stock valued at $2,726,000 after acquiring an additional 720 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Xenon Pharmaceuticals during the fourth quarter valued at $797,000. Barclays PLC grew its stake in Xenon Pharmaceuticals by 20.9% in the fourth quarter. Barclays PLC now owns 18,127 shares of the biopharmaceutical company’s stock valued at $711,000 after purchasing an additional 3,134 shares in the last quarter. XTX Topco Ltd purchased a new position in Xenon Pharmaceuticals in the fourth quarter valued at about $316,000. Finally, J. Safra Sarasin Holding AG acquired a new position in Xenon Pharmaceuticals in the 4th quarter worth about $697,000. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Price Performance

NASDAQ:XENE opened at $38.18 on Friday. The stock has a market cap of $2.94 billion, a P/E ratio of -10.75 and a beta of 1.16. Xenon Pharmaceuticals Inc. has a one year low of $26.74 and a one year high of $46.00. The company has a fifty day moving average price of $33.04 and a 200 day moving average price of $34.00.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Monday, August 11th. The biopharmaceutical company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.04). During the same period in the previous year, the company earned ($0.75) earnings per share. As a group, equities research analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Royal Bank Of Canada cut their price objective on shares of Xenon Pharmaceuticals from $57.00 to $55.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 12th. HC Wainwright restated a “buy” rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a report on Tuesday, May 13th. Wedbush upped their price objective on shares of Xenon Pharmaceuticals from $42.00 to $43.00 and gave the stock an “outperform” rating in a report on Tuesday, August 12th. Chardan Capital restated a “buy” rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday, August 12th. Finally, Needham & Company LLC decreased their price target on Xenon Pharmaceuticals from $60.00 to $55.00 and set a “buy” rating for the company in a research note on Tuesday, May 13th. Eleven investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $53.20.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.